p>Botulinum toxin’s role in aesthetic medicine is almost entirely defined by neuromodulation — relaxing overactive muscles to soften dynamic lines. But sebaceous glands are also a target of interest. Providers have used intradermal botulinum toxin off-label to reduce sebum production and improve acne in oily skin patients. What’s newer is the delivery method: a 2026 single-center observational study in the Journal of Cosmetic Dermatology tested whether botulinum toxin for oily skin could work transdermally — without needles — and still produce measurable sebum reduction.
What you will learn in this article:
Sebaceous glands receive cholinergic innervation. Botulinum toxin inhibits acetylcholine release, which is thought to reduce gland activity and sebum output. Schulz et al. reference this mechanism in their background section, and prior literature on intradermal botulinum toxin supports it.
The pathway is biologically plausible. It has not been proven for transdermal delivery specifically, but it provides a reasonable basis for testing whether needle-free delivery could produce a similar effect.
Patient interest in this space is real. These patients may not want wrinkle treatment. But many could benefit from a neuromodulator approach to sebaceous activity.
Needle-free delivery removes the barriers of needle aversion and injection contraindications. That expands the potential patient pool considerably.
Schulz and Lamprecht conducted a single-center observational study at Regenera Clinic in Barcelona in February and March 2024. The device was the DERMADROP MED TDA system. It holds CE-Class IIa approval in Europe but is not FDA-cleared for this indication in the U.S.
The delivery mechanism uses two components: a pressurized oxygen-assisted jet at approximately 265 m/s and a lipid-hydrophilic carrier matrix (LP3). Together, they transiently disrupt stratum corneum lipids to allow transdermal passage without structural barrier damage.
The protocol included a standardized microdermabrasion step before each treatment. This removed excess sebum and keratinized cells. It is part of the full BIOBOTOX protocol and affects how the results should be interpreted. The formulation used 50 IU of Bocouture (150 kDa), reconstituted in a 10% Argireline-containing solution. Each subject received 25 IU in a 12-minute standardized application.
The paper addresses Argireline directly. At 10% concentration, it “does not alter the fundamental transport characteristics of the LP3 carrier but primarily facilitates uniform dispersion of the reconstituted botulinum solution and provides minor surface-relaxing effects.” No separate arm isolated botulinum toxin’s contribution from the carrier formulation. That question remains open.
Nineteen participants enrolled (15 female, 4 male), ages 20–50, with oily and acne-prone skin and no prior facial interventions within 60 days. Assessments included Sebumeter SM815 measurements, QuantifiCare Mini 3D imaging, and 2D photography.
Two validated patient-reported outcome measures rounded out the evaluation: the Oily Skin Impact Scale (OSIS, which measures psychosocial burden) and the Oily Skin Self-Assessment Scale (OSSAS). Time points were baseline, two weeks, and four weeks post-treatment.
The study was funded by Meddrop BioMedical Technologies GmbH, the manufacturer of the DERMADROP device. Schulz is a Meddrop employee; Lamprecht received funding from Meddrop for study coordination. Both authors have a financial relationship with the sponsor. Spanish research guidelines did not require formal IRB approval for this study — the ethics statement classifies it as a noninvasive observational case study without experimental pharmaceuticals.
Sebumeter measurements showed numerical reductions across all assessed facial regions. However, only the forehead reached statistical significance. Readings fell from 166.75 to 100.19 mg/cm² — a 39.92% reduction (p<0.001).
For context, the manufacturer’s reference range places normal forehead skin at 100–180 mg/cm² and oily skin above 180 mg/cm². Other regions showed numerical improvements — cheeks −34%, chin −32%, nasal alae −26% — but none reached statistical significance.
Patient-reported outcomes told a more consistent story. On the OSIS, the Annoyance domain dropped 58% (5.50 to 2.30, p<0.001) and the Self-Image domain dropped 54% (4.90 to 2.23, p<0.001). On the OSSAS, visual oiliness perception fell 48%, sensory fell 57%, and tactile fell 49%. Overall self-assessment of facial oiliness improved by a mean of 3.79 points (t=8.31, p<0.001). These subjective improvements were strong and consistent across all domains.
The treatment was well-received. No erythema, edema, or pain occurred — consistent with the abstract’s “no adverse events” statement.
The full text adds nuance: mild post-treatment dryness occurred in a subset with sensitive or atopic skin. It resolved within three days. No flare-ups of acne, rosacea, or dermatitis occurred. For providers treating oily and acne-prone skin, that matters: the treatment did not exacerbate presenting conditions.
At the four-week follow-up, only eight of 19 participants provided questionnaire data. Among those eight, OSIS and OSSAS scores remained improved versus baseline.
The authors describe this as sustained benefit. However, the drop from 19 to 8 participants limits what conclusions about durability are possible.
This study’s design limits how far its findings can be taken. It is a single-center observational study with no control group and no sham arm. No placebo comparison exists. As a result, the relative contributions of botulinum toxin, Argireline, the LP3 carrier, the pre-treatment microdermabrasion, and patient expectation cannot be separated.
The authors’ own abstract concludes the treatment is “safe, well-tolerated, and effective” — language that goes further than the study design can support. A single-arm, n=19 study with no control produces directional evidence, not efficacy conclusions.
The study had no IRB approval. The authors classify it as a noninvasive observational case study under Spanish research guidelines, which did not require formal ethics board review. That classification is reasonable, but it is a meaningful limitation on evidence quality. Additionally, the results are device-specific. They apply to the DERMADROP MED device using the full BIOBOTOX protocol — including the pre-treatment step, specific formulation, and delivery parameters.
They do not generalize to transdermal botulinum toxin broadly. The device also holds CE-Class IIa approval in Europe but is not FDA-cleared for this indication in the U.S. That matters directly for providers in American markets.
There is also a measurement site issue worth naming. Each participant selected the two facial regions they identified as most oily for Sebumeter measurement. Not every region was measured for every participant. Forehead data came from approximately 16 of 19 participants, not all 19. Regional comparisons therefore use different sample sizes.
That further complicates interpreting why only the forehead reached significance. The paper does not document the regional n breakdown explicitly.
The four-week follow-up is short. Losing 11 of 19 participants at that point means long-term durability is unknown. The authors call for larger randomized controlled trials, optimal dosing research, and mechanistic studies before drawing conclusions. That framing — from the study’s own authors — is the right one to carry forward.
For now, this research is most useful as a signal to track rather than a protocol to adopt. If the technology advances and gains regulatory clearance, the patient population is distinct from the current injected neuromodulator market.
Three groups stand out: needle-averse patients who want sebum control without injections, acne-prone patients who are not seeking anti-wrinkle treatment, and patients contraindicated for injectables. A validated transdermal approach could eventually fill a gap for all three.
Some participants also spontaneously reported improvements in pigmentation spots and periorbital dark circles. The study did not target these as primary endpoints and did not control for them.
The paper documents them as exploratory findings only. The proposed mechanism involves enhanced microcirculation or improved oxygen delivery via the TDA system. This is hypothesis-generating, not confirmatory, but it points to a broader skin quality conversation beyond sebum control alone.
For providers building out their neuromodulator knowledge, IAPAM’s Certified Aesthetic Provider program covers botulinum toxin applications beyond standard anti-wrinkle use — including off-label sebum control and skin quality indications. The Aesthetic Medicine Symposium provides hands-on training for providers building or expanding their injectable practice.
Can Botox be used for oily skin or acne?
Providers have used intradermal botulinum toxin off-label to reduce sebum production and improve acne-prone skin. Prior clinical literature supports its efficacy via that delivery route. Transdermal delivery — needle-free — is newer and at an earlier evidence stage. This 2026 observational study reports preliminary results. However, a single-arm study with no control group cannot establish a clinical recommendation. Providers should follow the literature as it develops and evaluate regulatory status before incorporating any transdermal delivery approach into practice.
Does botulinum toxin reduce sebum production?
The proposed mechanism is inhibition of acetylcholine-mediated stimulation of sebaceous glands, which reduces their activity and sebum output. Prior literature on intradermal delivery supports this pathway. In this study, objective Sebumeter measurements showed a 40% reduction in forehead sebum — though only the forehead region reached statistical significance. Subjective patient-reported oiliness scores improved significantly across all domains. The mechanism is biologically plausible and the directional evidence is consistent. However, definitive proof from controlled trials is still needed.
What is transdermal botulinum toxin and how does it work?
Transdermal botulinum toxin refers to delivery of the toxin through the skin without needles. The DERMADROP MED system uses an oxygen-assisted jet at high velocity. It combines this with a multi-component carrier matrix — LP3 plus a 10% Argireline-containing solution. Together, they transiently disrupt the stratum corneum lipid structure. This allows the botulinum toxin formulation to penetrate into the epidermis and superficial dermis. The protocol in this study also included a pre-treatment microdermabrasion step. Whether the botulinum toxin reaches sebaceous glands at therapeutically relevant concentrations — separate from the carrier components — remains unconfirmed. Mechanistic studies have not yet addressed this.
Are there needle-free alternatives for botulinum toxin treatment?
The DERMADROP MED device represents one needle-free transdermal delivery platform for botulinum toxin. It holds CE-Class IIa approval in Europe but is not FDA-cleared for botulinum toxin delivery in the U.S. Other needle-free delivery technologies exist in the broader drug delivery space. However, none currently have validated clinical evidence for botulinum toxin and sebum control comparable even to this early-stage study. This remains an active area of development rather than an established treatment category.
Is needle-free Botox FDA-approved?
No. The DERMADROP MED device has CE-Class IIa approval in Europe, which means it passed the European conformity assessment process for a Class IIa medical device. CE approval is not equivalent to FDA clearance. In the U.S., the device is not FDA-cleared for transdermal botulinum toxin delivery. Botulinum toxin products are approved only for specific indications via injection. Any transdermal delivery of botulinum toxin in the U.S. would represent off-label use of both the device and the drug. That is a meaningful distinction for providers in American markets.
What’s the difference between intradermal and transdermal botulinum toxin delivery?
Intradermal delivery uses a needle to inject diluted botulinum toxin directly into the superficial dermis, where it acts on nearby sebaceous glands and sweat glands. This method has a more established evidence base for sebum reduction. Transdermal delivery attempts to move the toxin through intact skin without puncture, using a pressure-assisted carrier system. The advantage is the absence of needle-related discomfort, bruising, and the risk of toxin diffusion to facial muscles. The tradeoff is a weaker evidence base, device-specific dependence, and unresolved questions about toxin penetration depth and concentration compared to direct intradermal injection.
Discover proven techniques and industry insights to elevate your aesthetic practice. This comprehensive ebook covers essential protocols, patient safety, and advanced injection strategies used by top practitioners.
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!